NPSR1

Neuropeptide S receptor · Q6W5P4 · NPSR1 on Sugi Atlas →

1,937,014 patent compounds predicted against NPSR1, 1,139,740 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL496	0.43	7/20
SCHEMBL497	0.43	7/20
SCHEMBL10295	1.00	4/20
Camphoric Acid (SCHEMBL12308)	0.56	4/20
SCHEMBL7699	0.47	4/20
Megestrol Acetate (SCHEMBL745)	1.00	3/20
Medroxyprogesterone Acetate (SCHEMBL4276)	1.00	3/20
Medroxyprogesterone Acetate (SCHEMBL4277)	0.96	3/20
Ergotamine (SCHEMBL1483)	0.71	3/20
Melengestrol Acetate (SCHEMBL4520)	0.69	3/20
Ergotamine (SCHEMBL8045)	0.69	3/20
Ergotamine (SCHEMBL8046)	0.69	3/20
Cyproterone Acetate (SCHEMBL5936)	0.66	3/20
SCHEMBL3472	0.63	3/20
SCHEMBL8016	0.61	3/20
SCHEMBL9098	0.60	3/20
SCHEMBL4305	0.59	3/20
SCHEMBL257	0.58	3/20
Acrivastine (SCHEMBL4702)	0.57	3/20
Acrivastine (SCHEMBL4703)	0.57	3/20

Clinical trials — most relevant to NPSR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Neurosteroids for PTSD in Veterans	PHASE2	COMPLETED
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers	PHASE2	COMPLETED
Enoxolone in Major Depression - Biomarker-outcome Relationship	PHASE1/PHASE2	RECRUITING
The Effect of Ginger on the Incidence of Postoperative Nausea and Vomiting	PHASE2	COMPLETED
Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug	PHASE2	COMPLETED
Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches	PHASE2	COMPLETED
Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder	PHASE2	COMPLETED
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ	PHASE1	COMPLETED
RM1 Project 1 - tAN Naloxone	EARLY_PHASE1	RECRUITING
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Imaging CRF X NOP Interactions in CUD	EARLY_PHASE1	RECRUITING
[C-11]NPA PET-amphetamine in Cocaine Use Disorders	EARLY_PHASE1	RECRUITING
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors	nan	WITHDRAWN
Health Improvement for Baltimore Youth	nan	COMPLETED
Role of Substance P in Post-Traumatic Stress Disorder	nan	COMPLETED
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)	nan	RECRUITING
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression	nan	RECRUITING
Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
mGluR5 Imaging in ALS Using PET	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NPSR1 binder may also engage these)

Protein	Name	Similarity
Q8BZP8	—	1.000	Q8BZP8 →
Q56H79	—	1.000	Q56H79 →
P0C0L6	—	0.999	P0C0L6 →
Q28596	—	0.976	Q28596 →
TRHR	Thyrotropin-releasing hormone receptor	0.973	landscape →
Q01717	—	0.973	Q01717 →
P21761	—	0.973	P21761 →
BRS3	Bombesin receptor subtype-3	0.969	landscape →
O02835	—	0.968	O02835 →
Q04573	—	0.968	Q04573 →
O93603	—	0.968	O93603 →
O46639	—	0.967	O46639 →
P48303	—	0.967	P48303 →
P35382	—	0.967	P35382 →
PROKR2	Prokineticin receptor 2	0.966	landscape →
Q8K458	—	0.966	Q8K458 →
Q8SPN1	—	0.966	Q8SPN1 →
O97967	—	0.965	O97967 →
P17200	—	0.965	P17200 →
P30544	—	0.965	P30544 →
Q5IS62	—	0.965	Q5IS62 →
Q9WTV9	—	0.965	Q9WTV9 →
HTR2C	5-hydroxytryptamine receptor 2C	0.964	landscape →
Q9DDN6	—	0.964	Q9DDN6 →
O02836	—	0.964	O02836 →
P47751	—	0.963	P47751 →
Q9Z2D5	—	0.963	Q9Z2D5 →
O02813	—	0.963	O02813 →
Q91559	—	0.963	Q91559 →
Q868T3	—	0.963	Q868T3 →